Depression and Gender: Breaking Down Prevalence, Risk, and Treatment Differences

The conversation around depression is shifting—and for good reason. In a recent podcast episode, Alan Ogden explored the crucial topic of gender differences depression: why this condition doesn’t affect everyone equally, how treatment is evolving, and what the latest insights mean for individuals and communities. Drawing from decades in pharmacy and the latest technology in precision medicine, Alan examined how epidemiology, gender, and societal challenges—especially for veterans—shape the mental health landscape.

Epidemiology and Gender Differences in Depression

• Prevalence Rates Over a Lifetime and Annually

  According to Alan, “around 25 percent of the population at some point in their life will have a depressive episode and 8 percent in a given year.” These numbers highlight just how common depression is. But Alan is quick to remind us that even these figures may not capture the full picture, especially when anxiety disorders and other related conditions are included.

  “I read this and maybe you can clarify this for me. But one of the articles I read prior to changing from pharmacy to going to genetics was, and I believed it, that close to 60 percent of females in America, that includes Canada, the United States, had been on some sort of either anti-anxiety medication or something for depression, but some something to do with the challenge in their cognitive abilities. And that that was really shocking to me that, first of all, that it was needed. And second of all, that it was so misunderstood.”

  Alan describes his surprise at headlines or studies suggesting such high numbers of women have been prescribed mood or anxiety medications. While he also notes that those figures may reflect combined anxiety and depression treatments, the core message is clear: a substantial need exists, often without precise understanding or targeting of underlying causes.

• Gender Disparities in Depression

  The gender gap in depression is a focal point for Alan. He states unequivocally, “it’s twice as prevalent in women as it is in men”—so much so that he describes the ratio as “an eight to four ratio there to average out” for yearly prevalence rates. While women are more likely to experience depression, the risks for men take a different turn.

  “And so what we’re seeing is that even though it’s more prominent in women, unfortunately, and in men, it’s actually more likely to cause suicide. And so suicidality in men as a result of depression is higher.”

  This insight lays bare the dual challenge: women experience higher rates of diagnosed depression, but men’s depressive episodes more often lead to tragic outcomes. Alan emphasizes the importance of vigilance—by physicians, caregivers, and loved ones—to recognize the signs and ensure all people get the care and attention they need.

• Personalized Medicine: Turning Protocols Upside Down

  Traditional approaches to depression often involve a long, frustrating cycle of trial and error with medications. Alan, together with neurocare expert Talia Cohen-Salal, discusses innovative new directions in precision psychiatry that upend this model.

  “The premise is matching the right drug to the right patient instead of a patient trying to get better at the drug that isn’t suited to their biology. We create that pairing and help patients get better faster.”

  This new approach goes well beyond classic genetic testing. Patients can have a blood sample turned into neurons—essentially a “brain in a dish”—to test which medications will work best with their unique biology. Alan finds this shift thrilling, especially coming from his background in pharmacy where many people would return with half-full bottles of ineffective medication. The hope is to dramatically shorten the journey to recovery by targeting treatments accurately, accounting for individual variation in metabolism and brain chemistry.

Societal and Veteran Impact: Beyond the Numbers

• The Layered Impact on Veterans and First Responders

  Alan brings into focus a group often overlooked in general depression statistics: veterans and first responders. He mentions that in Canada, for example, the results of global conflicts leave many veterans—and first responders—struggling with PTSD and related trauma. While PTSD has its own clinical classification, Alan notes there is substantial overlap in both symptoms and treatment between PTSD and depression.

  “We have many veterans that, you know, have are suffering from PTSD, first line responders that are going through very, very traumatic incidents…a lot of the drugs that are being used are overlapping antidepressant drugs, antidepressants are being used for PTSD.”

  While clinical trials are ongoing to refine treatments specifically for PTSD, some physicians are already using new pharmacogenetic protocols off-label to support these populations. The key, Alan says, is expanding options and precision, not simply cycling through medications in the hope something works.

• The Socioeconomic Context: Challenges and Solutions

  Depression doesn’t exist in a vacuum. Alan touches on how social policy experiments—such as providing free drug centers in certain regions—aimed to address crime linked to substance use, but sometimes had the unintended consequence of drug diversion. The lesson is clear: solutions for depression and mental health must account for broader context, from economic hardship to community support, not just the individual biology.

  Personal experience matters too. Alan discusses how his own journey as a brain injury survivor has driven his interest in cellular health, especially in optimizing brain detoxification and glial cell function:

  “Certainly we have this abundance of cells in our brain who one of their main functions is the production of glutathione. And that’s something that I personally studied, having been a brain injury survivor, making sure that the detoxification mechanisms in my brain are optimized…”

  This holistic perspective—honoring both cutting-edge science and lived experience—broadens the ways people can access more precise, effective help for depression, whatever their circumstances.

• Hormonal Factors and Early Disruption

  Alan also highlights another important trend: earlier disruptions in hormone panels in both men and women. While these changes manifest differently (for example, declining testosterone in young men or cycle irregularities in women), they add another layer to the risk profile for depression. Alan connects these trends with modern lifestyle factors such as stress and sleep disruption, underscoring the value of a truly personalized approach that considers hormones, genetics, and environment together.

Conclusion: Rethinking Depression Through a Gendered, Personalized Lens

The landscape for understanding and treating depression is evolving, thanks in part to voices like Alan’s who bridge pharmacy, genetics, and personal experience. The takeaways are clear:

• Depression is common, but not evenly distributed: Women experience it at higher rates, while men face higher risks of suicide as a result of depression.
• Personalized medicine holds promise: Precision approaches may cut through the old trial-and-error cycle and get people the help they need faster.
• Societal context matters: From veterans’ experiences to socioeconomic challenges, solutions must look wider than the prescription pad.

If you’re interested in exploring how precision genetics can help tailor treatment to your unique biology—or if you’re concerned about yourself or a loved one—Alan encourages you to seek out providers who consider every facet of your story. Want to learn more? Listen to the full podcast episode or reach out to a precision health team to see what personalized care could look like for you.